SARC029: A Phase 2 Study of Trametinib in Combination With Pazopanib in Patients With Advanced GIST (Gastrointestinal Stromal Tumor) Refractory or Intolerant to at Least Imatinib and Sunitinib
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Pazopanib (Primary) ; Trametinib (Primary)
- Indications Gastrointestinal cancer
- Focus Therapeutic Use
- 08 Mar 2017 Status changed from not yet recruiting to withdrawn prior to enrolment as supporting company withdrew interest
- 28 Mar 2016 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020 as reported by ClinicalTrials.gov.
- 28 Mar 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.